NCT00282048View on ClinicalTrials.gov

Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

February 28, 2009

Study Completion Date

June 30, 2009

Conditions
Kidney NeoplasmsCarcinoma, Renal Cell
Interventions
DRUG

AG-013736 (axitinib)

AG-013736 5 mg twice daily \[bid\] continuous dosing in 28 day cycles.

Trial Locations (5)

10466

Pfizer Investigational Site, The Bronx

44195

Pfizer Investigational Site, Cleveland

53792

Pfizer Investigational Site, Madison

60637

Pfizer Investigational Site, Chicago

19111-2497

Pfizer Investigational Site, Philadelphia

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY